Hims & Hers (HIMS) CEO responds to Novo Nordisk (NVO) news

Statement on X by Hims & Hers (NYSE: HIMS) CEO Andrew Dudum:

"We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision making of providers and limit patient choice. We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients."

You May Also Be Interested In

• Heartflow (HTFL) Files for Proposed IPO
• Truist Financial Corp. (TFC) announces redemption of July 2026 senior notes
• FedEx (FDX) Announces Resignation of Chief Digital and Information Officer and Chief Transformation Officer Sriram Krishnasamy